Company: SION
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001193125-25-022709
Chunk: 97

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-07
Form: 424B4
Chunk 97
---
 | adverse regulatory decisions, including the failure to authorize or approve the conduct of one or more clinical trials of                                                                                 
 our product candidates, the failure to receive regulatory approvals of our product candidates, or the failure of a regulatory authority to accept data from clinical trials conducted in other countries; |

| • |     | the reporting of unfavorable preclinical or clinical results; |

| • |     | our success or failure to identify, develop, acquire or license additional product candidates; |

| • |     | the degree and rate of physician and market adoption of any of our current and future product candidates, if successfully 
 developed and approved;                                                                                                   |

| • |     | manufacturing, supply or distribution delays or shortages, including our inability to obtain adequate supply of drug                             
 product, drug substance, raw materials or any commercially available product to be used in our clinical trials, at acceptable prices, or at all; |

| • |     | developments or disputes concerning patent applications, issued patents or other proprietary rights; |

| • |     | unanticipated serious safety concerns related to the use of our product candidates or any other product candidate; |

| • |     | our cash position, and any changes in financial estimates by us or by any equity research analysts who might cover our 
 stock;                                                                                                                 |

| • |     | changes in our capital structure, such as future issuances of securities and the incurrence of additional debt; |

| • |     | conditions or trends in our industry; |

69

| • |     | investors’ general perception of our company and our business; |

| • |     | our ability to effectively manage our growth; |

| • |     | overall performance of the equity markets; |

| • |     | changes in the market valuations and stock market price and volume fluctuations of comparable companies and, in particular, 
 those that operate in the biopharmaceutical industry;                                                                       |

| • |     | publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research 
 coverage by securities analysts;                                                                                           |

| • |     | announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, capital 
 commitments or divestitures;                                                                                          |

| • |     | third-party publications and discussions about our business on social media, forums and other websites; |

| • |     | recruitment or departure of key personnel; |

| • |     | trading volume of our common stock; |

| • |     | sales of common stock by us or our